• L&C Bio will repurchase KRW 15 billion of its third-series convertible bonds on Nov. 23, 2026, through its call option.
• The bonds will be canceled, eliminating the series’ remaining outstanding balance ahead of its April 23, 2029 maturity.
• Funding will come from proceeds of a shareholder rights offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. L&C Bio Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261109000134), on November 09, 2026, and is solely responsible for the information contained therein.